SCYNEXIS Yönetim
Yönetim kriter kontrolleri 2/4
SCYNEXIS' CEO is David Angulo, appointed in Jan 2023, has a tenure of 1.83 years. total yearly compensation is $1.21M, comprised of 46.5% salary and 53.5% bonuses, including company stock and options. directly owns 0.38% of the company’s shares, worth $192.17K. The average tenure of the management team and the board of directors is 2.1 years and 9.5 years respectively.
Anahtar bilgiler
David Angulo
İcra Kurulu Başkanı
US$1.2m
Toplam tazminat
| CEO maaş yüzdesi | 46.5% |
| CEO görev süresi | 1.8yrs |
| CEO sahipliği | 0.4% |
| Yönetim ortalama görev süresi | 2.1yrs |
| Yönetim Kurulu ortalama görev süresi | 9.5yrs |
Son yönetim güncellemeleri
Recent updates
Is SCYNEXIS (NASDAQ:SCYX) Using Too Much Debt?
Aug 08
Lacklustre Performance Is Driving SCYNEXIS, Inc.'s (NASDAQ:SCYX) 32% Price Drop
Jun 19SCYNEXIS, Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year
May 12SCYNEXIS (NASDAQ:SCYX) Seems To Use Debt Rather Sparingly
Apr 04Scynexis: Update Following Restructuring Of GSK Deal
Apr 02Lacklustre Performance Is Driving SCYNEXIS, Inc.'s (NASDAQ:SCYX) Low P/S
Feb 01Does SCYNEXIS (NASDAQ:SCYX) Have A Healthy Balance Sheet?
Dec 21Little Excitement Around SCYNEXIS, Inc.'s (NASDAQ:SCYX) Revenues As Shares Take 28% Pounding
Sep 26Is SCYNEXIS (NASDAQ:SCYX) Using Too Much Debt?
Aug 17Scynexis: Uninvestible At This Point, Downgrading To A Sell Rating
Aug 26SCYNEXIS Q2 2022 Earnings Preview
Aug 12FDA accepts Scynexis' application to expand label for vaginal yeast infections treatment
Aug 01SCYNEXIS gains after favorable data for antifungal agent in new indication
Jul 19SCYNEXIS, Inc. (NASDAQ:SCYX) Analysts Just Cut Their EPS Forecasts Substantially
Apr 07SCYNEXIS, Inc.: Speculative Buy, Michael Burry Sold, But I Am Buying
Mar 07Some Analysts Just Cut Their SCYNEXIS, Inc. (NASDAQ:SCYX) Estimates
Feb 13Is SCYNEXIS (NASDAQ:SCYX) Using Debt In A Risky Way?
Dec 03Scynexis: Leading The Yeast Infection Treatment Industry
Jul 27Scynexis' Brexafemme qualifies for 10 years of exclusivity for vaginal yeast infections
Jun 09FDA approves SCYNEXIS' BREXAFEMME vaginal yeast infections treatment
Jun 02Is SCYNEXIS (NASDAQ:SCYX) Using Too Much Debt?
Apr 13Market Sentiment Around Loss-Making SCYNEXIS, Inc. (NASDAQ:SCYX)
Mar 15CEO Tazminat Analizi
| Tarih | Toplam Tazminat | Maaş | Şirket Kazançları |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -US$35m |
| Mar 31 2024 | n/a | n/a | US$101m |
| Dec 31 2023 | US$1m | US$565k | US$67m |
| Sep 30 2023 | n/a | n/a | US$72m |
| Jun 30 2023 | n/a | n/a | US$44m |
| Mar 31 2023 | n/a | n/a | -US$91m |
| Dec 31 2022 | US$1m | US$482k | -US$63m |
| Sep 30 2022 | n/a | n/a | -US$78m |
| Jun 30 2022 | n/a | n/a | -US$49m |
| Mar 31 2022 | n/a | n/a | -US$34m |
| Dec 31 2021 | US$987k | US$461k | -US$33m |
| Sep 30 2021 | n/a | n/a | -US$46m |
| Jun 30 2021 | n/a | n/a | -US$45m |
| Mar 31 2021 | n/a | n/a | -US$53m |
| Dec 31 2020 | US$939k | US$447k | -US$55m |
| Sep 30 2020 | n/a | n/a | -US$27m |
| Jun 30 2020 | n/a | n/a | -US$36m |
| Mar 31 2020 | n/a | n/a | -US$38m |
| Dec 31 2019 | US$1m | US$437k | -US$54m |
| Sep 30 2019 | n/a | n/a | -US$37m |
| Jun 30 2019 | n/a | n/a | -US$29m |
| Mar 31 2019 | n/a | n/a | -US$31m |
| Dec 31 2018 | US$769k | US$424k | -US$12m |
| Sep 30 2018 | n/a | n/a | -US$22m |
| Jun 30 2018 | n/a | n/a | -US$31m |
| Mar 31 2018 | n/a | n/a | -US$24m |
| Dec 31 2017 | US$768k | US$412k | -US$25m |
Tazminat ve Piyasa: David's total compensation ($USD1.21M) is above average for companies of similar size in the US market ($USD655.65K).
Tazminat ve Kazançlar: David's compensation has increased whilst the company is unprofitable.
CEO
David Angulo (59 yo)
1.8yrs
Görev süresi
US$1,214,710
Tazminat
Dr. David Gonzalez Angulo, M. D., had been the Chief Medical Officer at SCYNEXIS, Inc. since June 1, 2015. He is President, Director and Chief Executive Officer of SCYNEXIS, Inc. from January 1, 2023. Dr....
Liderlik Ekibi
| İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
|---|---|---|---|---|
| CEO, President & Director | 1.8yrs | US$1.21m | 0.38% $ 192.2k | |
| Chief Financial Officer | 2.1yrs | US$626.90k | 0.028% $ 14.0k | |
| Chief Legal Officer & Corporate Secretary | 7yrs | US$936.70k | 0.21% $ 106.6k | |
| Vice President of Human Resources & Information Technology | no data | Veri yok | Veri yok |
2.1yrs
Ortalama Görev Süresi
59yo
Ortalama Yaş
Deneyimli Yönetim: SCYX's management team is considered experienced (2.1 years average tenure).
Yönetim Kurulu Üyeleri
| İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
|---|---|---|---|---|
| CEO, President & Director | 1.8yrs | US$1.21m | 0.38% $ 192.2k | |
| Independent Director | 5.8yrs | US$98.75k | 0.066% $ 33.4k | |
| Independent Director | 9.2yrs | US$104.25k | 0.061% $ 30.9k | |
| Independent Director | 15.9yrs | US$105.25k | 0.062% $ 31.5k | |
| Independent Chairman of the Board | 10yrs | US$128.75k | 0.085% $ 42.7k | |
| Independent Director | 9.8yrs | US$106.25k | 0.063% $ 32.0k | |
| Member of Scientific Advisory Board | no data | Veri yok | Veri yok | |
| Member of Scientific Advisory Board | no data | Veri yok | Veri yok | |
| Member of Scientific Advisory Board | no data | Veri yok | Veri yok | |
| Member of Scientific Advisory Board | no data | Veri yok | Veri yok | |
| Member of Scientific Advisory Board | no data | Veri yok | Veri yok | |
| Member of Scientific Advisory Board | no data | Veri yok | Veri yok |
9.5yrs
Ortalama Görev Süresi
65.5yo
Ortalama Yaş
Deneyimli Yönetim Kurulu: SCYX's board of directors are considered experienced (9.5 years average tenure).